Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.
We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
Ristori
G
G
Department of Neurological Sciences, Università La Sapienza, Rome, Italy.
Buzzi
M G
MG
Sabatini
U
U
Giugni
E
E
Bastianello
S
S
Viselli
F
F
Buttinelli
C
C
Ruggieri
S
S
Colonnese
C
C
Pozzilli
C
C
Salvetti
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012008:Recurrence; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine